As well as counteracting cancer-related immunosuppression and enhancing antigen presentation, chemotherapy medications enhance the PD-L1 expression implicated in chemoresistance, through the synergistic combination of the PD-1/PD-L1 axis blockade with standard chemotherapeutic regimens [6, 7]. Here, CD274 is linked to cancer.